Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

<p><strong>Background</strong> The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks. The planned roll-...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Voysey, M, Costa Clemens, SA, Madhi, SA, Folegatti, PM, Aley, PK, Angus, B, Bibi, S, Cicconi, P, Clutterbuck, EA, Dold, C, Emary, KRW, Ewer, KJ, Flaxman, A, Feng, S, Green, CM, Greenland, M, Jenkin, D, Joe, CCD, Kerridge, S, Marchevsky, NG, Minassian, AM, Mujadidi, Y, Phillips, DJ, Plested, E, Ramasamy, M, Ritchie, AJ, Robinson, H, Song, R, Snape, MD, Douglas, AD, Hill, AVS, Lambe, T, Gilbert, SC, Pollard, AJ
Beste egile batzuk:	Oxford COVID Vaccine Trial Group
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	Elsevier 2021

Antzeko izenburuak

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
nork: Emary, KRW, et al.
Argitaratua: (2021)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
nork: Marchevsky, NG, et al.
Argitaratua: (2022)

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow up of two randomised controlled trials
nork: Voysey, M, et al.
Argitaratua: (2023)

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
nork: Clemens, SAC, et al.
Argitaratua: (2021)

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
nork: Flaxman, A, et al.
Argitaratua: (2021)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
nork: Natalie Gabrielle Marchevsky, et al.
Argitaratua: (2022-07-01)

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
nork: Hillson, K, et al.
Argitaratua: (2021)

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
nork: Voysey, M, et al.
Argitaratua: (2020)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial
nork: Frater, J, et al.
Argitaratua: (2021)

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
nork: Ramasamy, MN, et al.
Argitaratua: (2020)

Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers
nork: Jeewandara, C, et al.
Argitaratua: (2021)

REATOGENICIDADE COM MEIA DOSE DA VACINA CHADOX1 NCOV-19 (AZD1222)
nork: Maria da Penha Gomes Gouvea, et al.
Argitaratua: (2022-01-01)

Immune responses to a single dose of the AZD1222/Covishield vaccine in health care workers
nork: Chandima Jeewandara, et al.
Argitaratua: (2021-07-01)

AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire.
nork: Swanson, PA, et al.
Argitaratua: (2021)

Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals
nork: Jeewandara, C, et al.
Argitaratua: (2022)

Kinetics of immune responses to the AZD1222/Covishield vaccine with varying dose intervals in Sri Lankan individuals
nork: Chandima Jeewandara, et al.
Argitaratua: (2022-04-01)

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial
nork: Li, G, et al.
Argitaratua: (2022)

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
nork: Costa Clemens, SA, et al.
Argitaratua: (2023)

Immune responses to a single dose of the AZD1222/Covishield vaccine at 16 weeks in individuals in Sri Lanka
nork: Jeewandara, C, et al.
Argitaratua: (2021)

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
nork: Barrett, J, et al.
Argitaratua: (2020)

T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a Phase 1/2 clinical trial
nork: Ewer, K, et al.
Argitaratua: (2020)

18-month longitudinal SARS COV-2 neutralizing antibody dynamics in haemodialysis patients receiving heterologous 3-dose vaccination (AZD-1222- AZD-1222- BNT162b2) in a lower middle income setting
nork: Ridma Prasadini Karunathilake, et al.
Argitaratua: (2024-05-01)

A Randomized Clinical Trial of a Fractional Low Dose of BNT162b2 Booster in Adults Following AZD1222
nork: Rapisa Nantanee, et al.
Argitaratua: (2022-06-01)

Kinetics of immune responses to SARS-CoV-2 proteins in individuals with varying severity of infection and following a single dose of the AZD1222
nork: Jayathilaka, D, et al.
Argitaratua: (2022)

Acute bilateral central serous chorioretinopathy in a young male after the first dose of Oxford/AstraZeneca AZD1222 (Covishield) vaccine
nork: Meenakshi Sindhu, et al.
Argitaratua: (2023-01-01)

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
nork: Folegatti, PM, et al.
Argitaratua: (2020)

Safety and Immunogenicity of a Heterologous Booster of Protein Subunit Vaccine MVC-COV1901 after Two Doses of Adenoviral Vector Vaccine AZD1222
nork: Shu-Hsing Cheng, et al.
Argitaratua: (2022-10-01)

Dynamicity and persistence of severe acute respiratory syndrome coronavirus-2 antibody response after double dose and the third dose with BBV-152 and AZD1222 vaccines: A prospective, longitudinal cohort study
nork: Debaprasad Parai, et al.
Argitaratua: (2022-08-01)

Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants
nork: Suvimol Niyomnaitham, et al.
Argitaratua: (2023-04-01)

Monitoring and active surveillance of adverse events following the booster dose of AZD1222 vaccine in people vaccinated with Sinopharm BBIBP-CorV: a cohort study
nork: Shahin Soltani, et al.
Argitaratua: (2025-02-01)

AZD1222 effectiveness against severe COVID-19 in individuals with comorbidity or frailty: the RAVEN cohort study
nork: Meeraus, W, et al.
Argitaratua: (2024)

Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
nork: Ramasamy, MN, et al.
Argitaratua: (2023)

SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa
nork: Adam Abdullahi, et al.
Argitaratua: (2022-10-01)

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
nork: Kriangkrai Tawinprai, et al.
Argitaratua: (2022-01-01)

PERSISTENCE AND DYNAMICITY OF SARS-COV-2 ANTIBODY RESPONSE AFTER DOUBLE DOSE OF BBV-152 AND AZD1222 VACCINES: A PROSPECTIVE, LONGITUDINAL, YEAR-LONG COHORT STUDY
nork: D. Bhattacharya, et al.
Argitaratua: (2023-05-01)

Single-dose SARS-CoV-2 vaccinations with either BNT162b2 or AZD1222 induce disparate Th1 responses and IgA production
nork: Michael Müller, et al.
Argitaratua: (2022-01-01)

Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial
nork: Zhijie Dai, et al.
Argitaratua: (2023-04-01)

Bioethical Crossroads: the Case of the Oxford- AstraZeneca azd1222 Vaccine Against covid-19
nork: Fabio Alberto Garzón Díaz
Argitaratua: (2024-08-01)

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review
nork: George Kroumpouzos, et al.
Argitaratua: (2022-03-01)

Is a single dose of ChAdOx1 nCoV‐19 vaccine (AZD1222) enough for people with prior SARS‐CoV‐2 infection or baseline seropositive status?
nork: Vikas Deswal, et al.
Argitaratua: (2022-10-01)